How a specific receptor in lung cells affects inflammation and injury
S1PR1 Mislocalization in Lung Endothelium Regulates Innate Immune Function and Mediates Inflammatory Lung Injury
This study is looking at how a specific receptor in lung cells affects inflammation and lung damage, with the goal of finding new ways to help people manage or prevent lung injuries.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Illinois at Chicago NIH-funded |
| Lab location | 1 site (Chicago, UNITED STATES) |
| Project ID | NIH-10914675 on NIH RePORTER |
What this research studies
This research investigates the role of the Sphingosine-1-phosphate receptor-1 (S1PR1) in lung endothelial cells and its impact on inflammation and lung injury. The study aims to understand how modifications to this receptor can switch lung cells from an anti-inflammatory state to an immune-active state, potentially leading to severe lung damage. By examining the signaling pathways involved, researchers hope to uncover new therapeutic targets for treating acute lung injury. Patients may benefit from insights gained about how to better manage or prevent lung inflammation and injury.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals with conditions that predispose them to acute lung injury, such as severe infections or inflammatory diseases.
Not a fit: Patients with chronic lung conditions that do not involve acute inflammatory responses may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that prevent or reduce acute lung injury in patients.
How similar studies have performed: Previous research has shown that targeting similar pathways in other inflammatory conditions has led to promising results, suggesting potential for success in this area as well.
Where this research is happening
Chicago, UNITED STATES
- University of Illinois at Chicago — Chicago, United States (Active)
Researchers
- Principal investigator: Mehta, Dolly — University of Illinois at Chicago
- Study coordinator: Mehta, Dolly
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.